Evaluation of the diagnostic accuracy of UBC^® Rapid in bladder cancer: a Swedish multicentre study

References

• Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59:997–1008.
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005;66:35–63.
   PubMed Web of Science ®Google Scholar
• Wiener HG, Mian C, Haitel A, et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol. 1998;159:1876–1880.
   PubMed Web of Science ®Google Scholar
• Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61:109–118.
   PubMed Web of Science ®Google Scholar
• Glas AS, Roos D, Deutekom M, et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol. 2003;169:1975–1982.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Soukup V, Pesl M, et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology. 2008;71:718–722.
   PubMed Web of Science ®Google Scholar
• Guo A, Wang X, Shi J, et al. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: a meta-analysis. CUAJ. 2014;8:1–6.
   Web of Science ®Google Scholar
• Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010;14:1–372.
   Web of Science ®Google Scholar
• Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2015;94:1–24.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karam JA, Lotan Y, et al. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol. 2008;10:120–135.
   PubMedGoogle Scholar
• Ritter R, Hennenlotter J, Kühs U, et al. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. Urol Oncol-Semin O I. 2014;32:1–8.
   PubMed Web of Science ®Google Scholar
• Ecke TH, Arndt C, Stephan C, et al. Preliminary results of a multicentre study of the UBC rapid test for detection of urinary bladder cancer. Anticancer Res. 2015;35:2651–2655.
   PubMed Web of Science ®Google Scholar
• Barak V, Goike H, Panaretakis KW, et al. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004;37:529–540.
   PubMed Web of Science ®Google Scholar
• Sumi S, Arai K, Kitahara S, et al. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta. 2000;296:111–120.
   PubMed Web of Science ®Google Scholar
• Sánchez-Carbayo M, Herrero E, Megías J, et al. Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder. Urology. 1999;54:656–661.
   PubMed Web of Science ®Google Scholar
• Giannopoulos A, Manousakas T, Gounari A. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol. 2001;166:470–475.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) version; 2010.
   Google Scholar
• Chou R, Gore JL, Buckley D, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med. 2015;163:922–911.
   PubMed Web of Science ®Google Scholar
• Falebita OA, Lee G, Sweeney P. Urine cytology in the evaluation of urological malignancy revisited: is it still necessary? Urol Int. 2010;84:45–49.
   PubMed Web of Science ®Google Scholar
• Viswanath S, Zelhof B, Ho E, et al. Is routine urine cytology useful in the haematuria clinic? Ann R Coll Surg Engl. 2008;90:153–155.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Vlahou A, Taylor JA, et al. Considerations on the use of urine markers in the management of patients with high-grade non–muscle-invasive bladder cancer. Urol Oncol-Semin O I. 2014;32:1069–1077.
   PubMed Web of Science ®Google Scholar
• Mian C, Lodde M, Haitel A, et al. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology. 2000;56:228–231.
   PubMed Web of Science ®Google Scholar
• Hakenberg OW, Fuessel S, Richter K, et al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology. 2004;64:1121–1126.
   PubMed Web of Science ®Google Scholar
• Sarosdy MF, Hudson MA, Ellis WJ, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology. 1997;50:349–353.
   PubMed Web of Science ®Google Scholar
• Moonen PMJ, Kiemeney LALM, Witjes JA. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. Eur Urol. 2005;48:951–956.
   PubMed Web of Science ®Google Scholar
• Boman H, Hedelin H, Holmäng S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol. 2002;167:80–83.
   PubMed Web of Science ®Google Scholar
• van der Aa MN, Steyerberg EW, Bangma C, et al. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J Urol. 2010;183:76–80.
   PubMed Web of Science ®Google Scholar